Perindoprilat

Research use only, not for human use.

Perindoprilat is an Angiotensin Converting Enzyme Inhibitor.

Perindoprilat is an Angiotensin Converting Enzyme Inhibitor. The mechanism of action of perindoprilat is as an Angiotensin-converting Enzyme Inhibitor.

Perindoprilat (1 μM, 10 days) treatment suppresses the angiotensin II production in HNSCC cells.Perindoprilat (40 μM, 3 days) treatment attenuates mesangial cell fibronectin level.Cell Viability Assay Cell Line:HNSCC cells Concentration:1 μM Incubation Time:10 days Result:Suppressed the angiotensin II production in HNSCC cells (P=0.028).Cell Viability Assay Cell Line:Human mesangial cells Concentration:40 μM Incubation Time:3 days Result:Resulted in decreases in MPCM-stimulated fibronectin levels of 19.4±0.6% (P<0.001) and 21.7±1.0% (P<0.001) for secreted and cell-associated fibronectin levels, respectively.

Perindoprilat (oral gavage; 1.5 mg/kg; once daily; 7 d) treatment improves cardiac function in mice with acute myocardial infarction and reduces the number of apoptotic myocardial cells.Perindoprilat (oral gavage; 1.5 mg/kg; once daily; 7 d) treatment reduces the expression levels of myocardial Bax and Bcl-2 in infarction zones of mice with acute myocardial infarction.Perindoprilat (oral gavage; 1.5 mg/kg; once daily; 7 d) treatment lowers the expression of myocardial TLR4/NF-κB in infarction zones in mice with acute myocardial infarction. Animal Model:C57BL/6J mice underwent coronary ligation Dosage:1.5 mg/kg Administration:Oral gavage; 1.5 mg/kg; once daily; 7 days Result:Exhibited markedly lowered the number of apoptotic myocardial cells in comparison with the acute myocardial infarction group (p<0.05).Animal Model:C57BL/6J mice underwent coronary ligation Dosage:1.5 mg/kg Administration:Oral gavage; 1.5 mg/kg; once daily; 7 days Result:Reduced the gene and protein expression levels of Bax (a myocardial apoptosis gene) in infarction zones in mice with acute myocardial infarction.Animal Model:C57BL/6J mice underwent coronary ligation Dosage:1.5 mg/kg Administration:Oral gavage; 1.5 mg/kg; once daily; 7 days Result:Declined the number of stained NF-κB p50 protein in the nucleus in infarction zones (p<0.05), compared to the acute myocardial infarction group.

S-9780

Endocrinology/Hormones

AChR

AChR| MRP| ACE

——

——

95153-31-4

340.41

C17H28N2O5

>98% (HPLC)

Soluble in DMSO

O=C([C@H]1N(C([C@H](C)N[C@H](C(O)=O)CCC)=O)[C@@]2([H])CCCC[C@@]2([H])C1)O

(2S,3aS,7aS)-1-(((S)-1-carboxybutyl)-L-alanyl)octahydro-1H-indole-2-carboxylic acid

(-20℃)

With Ice Pack

≥ 2 years